Selumetinib in Children with Inoperable Plexiform Neurofibromas

BACKGROUND: No approved therapies exist for inoperable plexiform neurofibromas in patients with neurofibromatosis type 1. METHODS: We conducted an open-label, phase 2 trial of selumetinib to determine the objective response rate among patients with plexiform neurofibromas and to assess clinical bene...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:N Engl J Med
Päätekijät: Gross, Andrea M., Wolters, Pamela L., Dombi, Eva, Baldwin, Andrea, Whitcomb, Patricia, Fisher, Michael J., Weiss, Brian, Kim, AeRang, Bornhorst, Miriam, Shah, Amish C., Martin, Staci, Roderick, Marie C., Pichard, Dominique C., Carbonell, Amanda, Paul, Scott M., Therrien, Janet, Kapustina, Oxana, Heisey, Kara, Clapp, D. Wade, Zhang, Chi, Peer, Cody J., Figg, William D., Smith, Malcolm, Glod, John, Blakeley, Jaishri O., Steinberg, Seth M., Venzon, David J., Doyle, L. Austin, Widemann, Brigitte C.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2020
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7305659/
https://ncbi.nlm.nih.gov/pubmed/32187457
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1912735
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia